Growth Hormone Peptides: The Complete Guide to GH Secretagogues (Sermorelin, Ipamorelin, CJC-1295, GHRP-2, Tesamorelin, Hexarelin)
Growth Hormone Peptides: The Complete Guide to GH Secretagogues
Introduction
After age 30, human growth hormone output declines at roughly 15% per decade — a process researchers call the somatopause. By 60, most adults are producing less than half the GH they had at 25. The downstream effects are visible across nearly every body system: visceral fat accumulates, lean mass decreases, recovery slows, sleep architecture degrades, and markers of biological aging accelerate. IGF-1 levels in a 70-year-old average roughly 50% of those measured in a healthy 25-year-old, and this upstream signaling deficit drives much of what we associate with "normal" aging.
The traditional intervention — injecting synthetic human growth hormone (HGH) — is blunt. It delivers continuous exogenous GH that bypasses the hypothalamic-pituitary feedback loops entirely, suppresses endogenous production, and carries regulatory and cost barriers that make it impractical for most researchers and clinicians. Perhaps more importantly, it replaces a pulsatile, feedback-governed system with a pharmacological baseline — which is not how GH is supposed to work.
GH secretagogues are the modern alternative. These peptides stimulate the pituitary gland to release its own growth hormone — preserving the pulsatile release pattern, maintaining somatostatin feedback integrity, and restoring the GH axis from the upstream signal rather than overriding it. The result is a physiological GH profile, not a flat blood level.
Six research peptides form the complete toolkit for GH axis modulation: Sermorelin, Ipamorelin, CJC-1295 / Mod-GRF(1-29), GHRP-2, Tesamorelin, and Hexarelin. This guide covers all six — mechanisms, clinical data, best use cases, and how to combine them intelligently.
The GH Axis: What You Need to Know
Growth hormone is not secreted continuously. It is released in discrete pulses — most prominently during slow-wave sleep (stages 3 and 4 of NREM) — governed by a feedback system involving three key players in the hypothalamic-pituitary axis:
- GHRH (growth hormone-releasing hormone): Released from the hypothalamus to stimulate GH secretion from the anterior pituitary somatotroph cells.
- Somatostatin: The inhibitory counterpart, also from the hypothalamus. It suppresses GH release and creates the trough periods between pulses — the "off switch" that prevents continuous secretion.
- Ghrelin / GH secretagogues: A third input class acting on GHS-R1a receptors in the pituitary and hypothalamus, amplifying GH release and partially suppressing somatostatin tone.
The pituitary releases GH into circulation, which acts directly on tissues and prompts the liver to produce IGF-1 (insulin-like growth factor 1) — the downstream mediator responsible for most of GH's anabolic, lipolytic, and tissue-repair effects. IGF-1 feeds back to suppress further GH release, completing the regulatory loop.
Two Receptor Classes: Why This Matters for Stacking
The six GH peptides in this guide work through two distinct receptor systems:
GHRH Receptors (GHRHR): Targeted by GHRH analogs — Sermorelin, CJC-1295/Mod-GRF(1-29), and Tesamorelin. These peptides mimic the hypothalamus's natural "go" signal, amplifying the height of each GH pulse while leaving somatostatin feedback intact.
Ghrelin/GHS-R1a Receptors: Targeted by GHRPs — Ipamorelin, GHRP-2, and Hexarelin. These peptides act at the "gatekeeper" step: they suppress somatostatin tone and open the window for GH release, independent of the GHRH signal.
This distinction is the mechanistic foundation for why combining one peptide from each class produces synergistic GH release that neither class can achieve alone. This is the stacking principle — and we will return to it in depth.
Why Pulsatility Matters
Physiological GH is a pulsatile signal — high-amplitude bursts followed by near-zero troughs. This architecture matters for two reasons.
First, pulsatile GH is what the body is calibrated to respond to. Continuous supraphysiological GH (as produced by synthetic HGH injection) triggers IGF-1 negative feedback and receptor downregulation, eventually diminishing sensitivity across the axis.
Second, the somatopause is fundamentally a pulsatility problem. It is not that the pituitary loses the capacity to release GH — it is that the pulses become smaller and less frequent. Restoring pulsatile signaling via secretagogues addresses the actual mechanism of decline, rather than simply replacing a downstream product.
The Six GH Peptides: Mechanism Depth
1. Sermorelin — The Anti-Aging Gold Standard
Mechanism: Sermorelin is a synthetic version of the first 29 amino acids of human GHRH — the biologically active N-terminal fragment known as GHRH(1-29). It binds GHRHR on pituitary somatotroph cells and stimulates GH secretion, while leaving somatostatin feedback entirely intact. The pituitary's natural "off switch" continues to function, making Sermorelin one of the most physiologically faithful options in the class.
Clinical Evidence: Sermorelin is the only GH secretagogue with FDA approval for human use — granted for pediatric growth hormone deficiency. On the adult side, Corpas et al. (1992) demonstrated that twice-daily Sermorelin administration in older men produced significant increases in GH pulsatility and IGF-1 levels over 6 months, restoring profiles closer to younger reference values. Walker and Bercu (1996) extended this work, confirming improved sleep quality, lean body mass changes, and favorable body composition trends in adult GHD populations. No other GH peptide has a comparable regulatory track record or multi-decade clinical history in humans.
Best Use Case: Anti-aging and longevity protocols; first GH peptide for axis optimization; clinical settings where regulatory track record matters most.
Stack Fit: Pairs cleanly with any GHRP — most commonly Ipamorelin for lowest side-effect profile. See the full Sermorelin guide.
2. Ipamorelin — The Clean GH Pulse
Mechanism: Ipamorelin is a pentapeptide GHRP and the most selective GHS-R1a agonist in clinical use. Its defining characteristic is selectivity: it releases growth hormone with minimal effect on cortisol, prolactin, ACTH, or aldosterone. Earlier GHRPs — particularly GHRP-6 — were effective GH stimulators but came with significant cortisol spikes and appetite dysregulation. Ipamorelin engineered selectivity into the molecule, producing a clean, isolated GH pulse.
Clinical Evidence: Raun et al. (1998) published the pivotal selectivity data, demonstrating in head-to-head animal studies that Ipamorelin produced comparable GH release to GHRP-6 without the cortisol or prolactin co-response. Human publication data is more limited compared to Sermorelin or Tesamorelin, but the preclinical selectivity profile is the most thoroughly characterized in the GHRP class. It remains the most widely used GHRP in research and clinical GH optimization protocols.
Best Use Case: Sleep-stack workhorse (pre-bed administration aligned with slow-wave sleep GH pulse), anti-aging protocols, users sensitive to cortisol, first-time GHRP users.
Stack Fit: The canonical pairing is with Sermorelin or Mod-GRF(1-29). Minimal tachyphylaxis risk. See the full Ipamorelin guide.
3. CJC-1295 / Mod-GRF(1-29) — The GHRH Amplifier
Mechanism: CJC-1295 and Mod-GRF(1-29) are both GHRH analogs — modified versions of GHRH(1-29) engineered for improved half-life. The critical distinction is the Drug Affinity Complex (DAC):
- CJC-1295 with DAC covalently binds albumin after injection, extending its half-life to approximately 6–8 days. This creates a continuous, low-level GHRH signal — a "GH bleed" — rather than discrete pulses. Pulsatility is sacrificed for convenience and sustained elevation.
- Mod-GRF(1-29) (CJC-1295 without DAC) has a half-life of 15–30 minutes. It amplifies a single GH pulse when injected, then clears quickly — preserving pulsatile architecture. This is the form recommended for physiological stacking protocols.
Clinical Evidence: Alba et al. (2006) published the primary human RCT on CJC-1295 with DAC, demonstrating dose-dependent increases in IGF-1 (up to 88% above baseline at peak) and sustained GH levels in healthy adults over weeks. The study confirmed pharmacokinetics and safety of the DAC formulation. Mod-GRF(1-29) is used in research practice based on mechanistic rationale extrapolated from the DAC trial and the broader GHRH literature.
Best Use Case: Mod-GRF(1-29) for pulsatile GH stack protocols; CJC-1295 with DAC for sustained IGF-1 elevation where pulsatility is secondary.
Stack Fit: Mod-GRF(1-29) + Ipamorelin is the canonical beginner GH stack — one from each receptor class, injected simultaneously for a clean, synergistic pulse. See the full CJC-1295 / Mod-GRF guide.
4. GHRP-2 — The High-Amplitude Intermediate
Mechanism: GHRP-2 is a synthetic hexapeptide with a dual mechanism: it is a potent GHS-R1a agonist (like Ipamorelin) but also exhibits mild GHRH-like activity at the pituitary level. This dual action makes it a more powerful GH releaser than Ipamorelin — but also a less selective one. GHRP-2 produces measurable cortisol and hunger stimulation, though significantly less than GHRP-6. The trade-off: higher GH pulse amplitude for a somewhat higher side-effect burden.
Clinical Evidence: Ghigo et al. (1994) provided early human data establishing GHRP-2's potent GH-releasing capacity and dose-response relationship in adults. Arvat et al. (1997) extended this work, characterizing cortisol and prolactin co-release and — critically — confirming the synergistic GH response when GHRP-2 is combined with a GHRH analog in humans. These are among the most rigorously conducted acute human studies in the GH peptide literature.
Best Use Case: Intermediate users seeking more GH output than Ipamorelin provides; body recomposition protocols where higher amplitude is prioritized; users who have completed an Ipamorelin protocol and want to step up.
Stack Fit: Pairs with Mod-GRF(1-29) for a potent recomposition stack. Not ideal for users sensitive to cortisol fluctuations or appetite dysregulation. See the full GHRP-2 guide.
5. Tesamorelin — The FDA-Approved Clinical Anchor
Mechanism: Tesamorelin is a GHRH analog with a modified trans-3-hexenoic acid group conjugated at the N-terminus. This modification protects the molecule from dipeptidyl peptidase IV (DPP-IV) cleavage, extending its half-life compared to native GHRH and enabling reliable subcutaneous pharmacokinetics. Like Sermorelin, Tesamorelin binds GHRHR and preserves somatostatin feedback. Its distinctive downstream effect is a pronounced increase in IGFBP-3 (IGF binding protein 3), which modulates IGF-1 bioavailability in a tissue-specific manner that appears particularly relevant to visceral fat metabolism.
Clinical Evidence: Tesamorelin is FDA-approved as Egrifta for the treatment of HIV-associated lipodystrophy — the only GHRH analog to achieve adult FDA approval. Falutz et al. (2007) published the landmark Phase III RCT demonstrating a 15.2% reduction in visceral adipose tissue (measured by CT scan) versus placebo over 26 weeks in HIV patients on antiretrovirals. Falutz et al. (2010) confirmed these effects in a larger extension study. Tesamorelin is the gold standard for clinical evidence in this class — no other GH peptide has comparable Phase III RCT data in adult humans.
Best Use Case: Visceral fat targeting; clinical GH axis restoration; advanced protocols where Phase III RCT evidence is a priority.
Stack Fit: Effective as a standalone (as used in the Falutz trials) or combined with a GHRP for enhanced pulse amplitude. At the advanced level, pairs with Mod-GRF and Hexarelin for a triple-layer protocol. See the full Tesamorelin guide.
6. Hexarelin — The Potent Outlier
Mechanism: Hexarelin is the most potent synthetic GHRP available — producing the largest GH pulse amplitude in the class by a meaningful margin. It is a GHS-R1a agonist with strong binding affinity at both pituitary and hypothalamic levels. What fundamentally differentiates Hexarelin from every other GH peptide in this guide is a secondary receptor target: CD36, a scavenger receptor expressed heavily in cardiac muscle. Hexarelin's interaction with CD36 produces cardioprotective and anti-ischemic effects that are entirely independent of the GH axis — a mechanism unique to Hexarelin in the entire GH peptide class.
The price of this potency is tachyphylaxis: GH receptor desensitization occurs significantly faster than with Ipamorelin or Sermorelin, typically apparent within 4–6 weeks of continuous use. Cycling protocols are non-negotiable.
Clinical Evidence: Rossoni et al. (1998) documented Hexarelin's direct cardiac receptor binding and cardioprotective effects independent of GH stimulation — mechanistically separating it from the rest of the class. Muccioli et al. (2004) characterized the CD36 binding mechanism and downstream anti-apoptotic effects on cardiomyocytes. Ghigo et al. (1996) established Hexarelin as the most effective GHRP in head-to-head acute GH release studies in humans.
Best Use Case: Advanced users requiring maximum GH pulse amplitude; researchers with a specific interest in cardiac biology; protocols where cardioprotective effects are a secondary target.
Stack Fit: Pairs with Mod-GRF(1-29) for a high-amplitude two-class stack. Add Tesamorelin for simultaneous visceral fat targeting. Must be cycled: 8 weeks on / 4 weeks off minimum. See the full Hexarelin guide.
GHRH vs GHRP: The Stacking Principle
Understanding why GH peptides are always combined across classes — rather than doubling up within one class — requires understanding the two distinct physiological constraints that normally govern GH release.
Constraint 1 — Amplitude: GHRH receptors on pituitary somatotrophs control how much GH is released per pulse. GHRH analogs (Sermorelin, Mod-GRF, Tesamorelin) work at this level — they amplify signal strength.
Constraint 2 — The somatostatin gate: Somatostatin is the inhibitory peptide that suppresses GH release regardless of how much GHRH is present. GHRPs (Ipamorelin, GHRP-2, Hexarelin) work at this level — they suppress somatostatin tone, opening the release window.
When you use a GHRH analog alone, you amplify the signal — but somatostatin can still blunt the response. When you use a GHRP alone, you clear the somatostatin gate — but the signal amplitude remains limited. When you combine both classes:
- The GHRP suppresses somatostatin — opening the release window.
- The GHRH analog fires into that clear window at full amplitude.
- The result is synergistic, not merely additive.
Smith et al. (1997) quantified this synergy directly: GHRP alone produces approximately 3–5x GH increase above baseline; GHRH analog alone produces approximately 2–3x. Combined, the response reaches 8–12x baseline — a magnitude neither class approaches independently. This is why every serious GH protocol in the research and clinical literature uses a GHRH + GHRP combination.
Practical rule: Never use a GHRH analog or a GHRP in isolation if maximal GH output is your goal. The combination is not optional — it is the mechanism.
Stack Protocols
Protocol 1: Beginner Anti-Aging Stack
Compounds: Sermorelin + Ipamorelin
Why this combination: The safest option in the class. Sermorelin's somatostatin-feedback preservation and decades-long regulatory track record pair with Ipamorelin's selectivity (negligible cortisol, negligible prolactin). The combined side-effect profile is lower than any other GHRH + GHRP pairing.
Timing: 30 minutes before sleep, 5 nights per week (Monday–Friday, rest on weekend). Pre-sleep timing aligns with the natural slow-wave sleep GH pulse, maximizing the stimulus.
Cycle: 3–6 months on, 4–6 weeks off. Sermorelin has low tachyphylaxis risk; Ipamorelin has essentially none.
Goal: Restoring youthful GH pulsatility, improving sleep quality, supporting lean mass and recovery in the 40+ population.
Protocol 2: Intermediate Body Recomposition Stack
Compounds: Mod-GRF(1-29) + GHRP-2
Why this combination: Stronger GH pulse amplitude than Protocol 1. Mod-GRF's short half-life (15–30 minutes) preserves pulsatile architecture. GHRP-2 provides more GH output than Ipamorelin, supporting more pronounced recomposition effects — at the cost of mild cortisol and appetite stimulation that most users manage without issue.
Timing: 2x per day — AM fasted (immediately after waking, before food) and pre-sleep. The AM fasted window is essential: elevated free fatty acids from recent food blunt GH release, so an overnight-fasted injection gives peptides a metabolically clear window to work.
Cycle: 5 days on / 2 days off, or 4 weeks on / 1 week off. Cycling reduces GHRP-2's moderate tachyphylaxis risk.
Goal: Body recomposition — simultaneous fat loss and lean mass support.
Protocol 3: Advanced Performance Stack
Compounds: Mod-GRF(1-29) + Hexarelin + Tesamorelin
Why this combination: Maximum-output GH protocol. Hexarelin's superior GH pulse amplitude pairs with Mod-GRF's GHRH amplification for peak response. Tesamorelin is added specifically for visceral fat — its IGFBP-3 modulation and fat-targeting mechanism complement Hexarelin's muscle and performance focus. The triple layer addresses GH amplitude, body composition, and visceral fat simultaneously.
Critical constraint: Hexarelin's tachyphylaxis is significant. This protocol requires strict 8 weeks on / 4 weeks off cycling. Extending on-cycles beyond 8 weeks will produce diminishing returns, and recovery to full sensitivity may take longer than the standard 4-week washout.
Timing: Mod-GRF + Hexarelin pre-sleep and/or AM fasted. Tesamorelin once daily (as used in the Falutz trial protocol).
Goal: Peak body recomposition, advanced performance, visceral fat reduction.
Protocol 4: Longevity + Sleep Optimization Stack
Compounds: Sermorelin + Ipamorelin + Epithalon
Why this combination: The cross-cluster longevity stack. Sermorelin + Ipamorelin handle GH axis restoration as in Protocol 1. Epithalon is added for its downstream effects on circadian rhythm regulation and GH pulse amplitude — Khavinson's research shows that Epithalon specifically enhances the nighttime GH surge by modulating pineal function and somatotroph sensitivity. The combination addresses pulsatile GH, sleep architecture, and telomerase activation in a single pre-sleep protocol.
Timing: All three compounds 30 minutes before sleep, 5 nights per week.
Cycle: Epithalon is typically run in 10-day courses every 3–6 months. Sermorelin + Ipamorelin continue between Epithalon courses as the base protocol.
Goal: Longevity, sleep quality, anti-aging, GH axis restoration in the 50+ age group.
The complete GH stacking protocols, timing guides, cycle templates, dosing math, and bloodwork monitoring guidance are in the Peptide Stacking Guide. Get the Stacking Guide — $14.99 →
6-Column Comparison Table
| Peptide | Class | Receptor | GH Potency | Selectivity | Best Use Case |
|---|---|---|---|---|---|
| Sermorelin | GHRH analog | GHRHR | Moderate | High — SS feedback preserved | Anti-aging, beginner protocol |
| Ipamorelin | GHRP | GHS-R1a | Moderate | Highest — no cortisol/prolactin | Sleep stack, anti-aging |
| CJC-1295 / Mod-GRF(1-29) | GHRH analog | GHRHR | Moderate–High | High — pulsatile form preferred | GHRH amplifier for any GHRP stack |
| GHRP-2 | GHRP | GHS-R1a | High | Moderate — mild cortisol/hunger | Recomposition, intermediate users |
| Tesamorelin | GHRH analog | GHRHR | Moderate–High | High — SS feedback preserved | Visceral fat, clinical protocol |
| Hexarelin | GHRP | GHS-R1a + CD36 | Highest | Lower — tachyphylaxis risk | Advanced performance, cardiac |
Clinical Evidence: An Honest Summary
The evidence landscape for GH peptides is uneven, and being honest about that unevenness is important for anyone designing a protocol.
Tesamorelin has the strongest adult human evidence: two Phase III RCTs (Falutz 2007, 2010) demonstrating significant visceral fat reduction in a well-defined patient population, with FDA approval as the outcome. If you need the best-validated GHRH analog in the class, this is it.
Sermorelin has the longest regulatory track record — FDA-approved for pediatric GHD since the 1990s — and positive adult GHD studies (Corpas 1992, Walker and Bercu 1996). These are not large Phase III industry trials, but they are well-designed published studies in adults, and the decades-long clinical use history is unique in this class.
CJC-1295 has one published human RCT (Alba 2006), using the DAC formulation, demonstrating dose-dependent IGF-1 elevation. The Mod-GRF(1-29) form is used empirically, based on mechanistic rationale and the broader GHRH literature.
GHRP-2 and Hexarelin both have strong acute human study data. Arvat (1997), Ghigo (1994), and Ghigo (1996) are rigorously conducted studies characterizing GH release, cortisol co-secretion, and GHRH synergy in humans. What they lack is long-term RCT evidence — these are acute characterization studies, not multi-week controlled trials.
Ipamorelin has the most extensive preclinical selectivity data (Raun 1998) but the thinnest human publication record. It remains the most widely used GHRP in clinical and research settings precisely because its selectivity profile is well-characterized, even if formal human trials are sparse.
The honest bottom line: Most GH peptide use in the biohacking and clinical optimization communities is empirical — informed by mechanism, acute human data, and established research protocols, but running ahead of long-term RCT evidence for several compounds. Tesamorelin and Sermorelin are the credibility anchors for the class. The GHRPs are backed by compelling mechanisms and convincing acute human studies. Use evidence level as a guide for protocol design, not as a binary filter — the mechanism story for this entire class is well-established biology, even where the clinical trial literature is thin.
Conclusion
The growth hormone axis is the most thoroughly studied peptide target in aging and performance biology. Decades of research on GHRH receptors, ghrelin receptors, somatostatin dynamics, and GH pulse physiology have produced a precise mechanistic understanding of how to modulate this system — and six specific peptides to do it with.
The evidence supports a clear progression: start with the best-characterized compounds (Sermorelin + Ipamorelin for Protocol 1), advance toward higher-output combinations (Mod-GRF + GHRP-2 for Protocol 2, Mod-GRF + Hexarelin for Protocol 3), and use Tesamorelin when FDA-validated visceral fat effects are the specific goal. Add Epithalon to the longevity stack to address the circadian upstream layer. Always combine a GHRH-class peptide with a GHRP-class peptide — the synergy is the mechanism, not a nice-to-have.
For the practical side — vial preparation, injection technique, and the math behind dosing concentrations — the reconstitution guide covers everything before your first injection.
New to peptide research? The Peptide 101 Complete Bundle includes the Beginner's Guide and the Stacking Guide — everything you need to start your first GH protocol with confidence. Get the Complete Bundle — $19.99 →
Medical Disclaimer
This article is for educational purposes only. It does not constitute medical advice and does not establish a doctor-patient relationship. The peptides discussed are research compounds. Sermorelin and Tesamorelin have FDA approval for specific indications; the other peptides in this article are not FDA-approved for the prevention, treatment, or cure of any disease. Claims regarding mechanisms, clinical evidence, and protocols are based on published preclinical and clinical research as cited — not on FDA-validated labeling. Do not begin any peptide protocol without consulting a qualified healthcare provider familiar with peptide therapy and your individual medical history. Peptide 101 provides education about research compounds; we do not sell peptides. Source any research compound responsibly, verify purity via third-party certificate of analysis, and use at your own risk.